Burden and challenges of heart failure in patients with chronic kidney disease. A call to action

Romero‐González, Gregorio; Ravassa, Susana; González, Omar; Lorenzo, Ignacio; Rojas, Miguel; García-Trigo, Isabel; García-Fernández, Núria; Lavilla, Javier; Martín, Paloma Leticia; López, Begoña; González, Arantxa; Beaumont, Francisco J.; José, Gorka San; Moreno, María U.; Ania, Noelia; Osácar, Elena; Amézqueta, Pilar; Dı́ez, Javier

doi:10.1016/j.nefro.2019.10.005

Cited by 27 publications

(20 citation statements)

References 101 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Increasing the knowledge about HF costs and their determinants is important in order to ascertain how HF management can be optimized, leading to a significant decrease of HF costs [3,7,11,12]. Unfortunately, data about costs of HF in Spain are very scarce or limited to the use of specific drugs, but not focused on a comprehensive approach [13][14][15][16][17][18]. For example, a study performed in Spain in 2014 among only 374 patients reported a high total cost associated with HF [18].…”

Section: Introductionmentioning

confidence: 99%

Costs and healthcare utilisation of patients with heart failure in Spain

Cervantes

Varela

Palacios

et al. 2020

BMC Health Serv Res

View full text Add to dashboard Cite

Background Increasing the knowledge about heart failure (HF) costs and their determinants is important to ascertain how HF management can be optimized, leading to a significant decrease of HF costs. This study evaluated the cumulative costs and healthcare utilisation in HF patients in Spain. Methods Observational, retrospective, population-based study using BIG-PAC database, which included data from specialized and primary care of people ≥18 years, from seven autonomous communities in Spain, who received care for HF between 2015 and 2019. The healthcare and medication costs were summarized on a yearly basis starting from the index date (1st January 2015), and then cumulatively until 2019. Results We identified 17,163 patients with HF (year 2015: mean age 77.3 ± 11.8 years, 53.5% men, 51.7% systolic HF, 43.6% on NYHA functional class II). During the 2015–2019 period, total HF associated costs reached 15,373 Euros per person, being cardiovascular disease hospitalizations the most important determinant (75.8%), particularly HF hospitalizations (51.0%). Total medication cost accounted for 7.0% of the total cost. During this period, there was a progressive decrease of cardiovascular disease hospital costs per year (from 2834 Euros in 2015 to 2146 Euros in 2019, P < 0.001), as well as cardiovascular and diabetic medication costs. Conclusions During the 2015–2019 period, costs of HF patients in Spain were substantial, being HF hospitalizations the most important determinant. Medication costs represented only a small proportion of total costs. Improving HF management, particularly through the use of drugs that reduce HF hospitalization may be helpful to reduce HF burden.

show abstract

Section: Introductionmentioning

confidence: 99%

Costs and healthcare utilisation of patients with heart failure in Spain

Cervantes

Varela

Palacios

et al. 2020

BMC Health Serv Res

View full text Add to dashboard Cite

show abstract

“…9,10 However, this finding is higher than findings reported from Spain (0.17 to 0. 21) 11 and America (0.38). 12 The above variations between studies could be explained, in part, by the differences in sample size, study settings, follow-up period, and socio-demographic characteristics of study participants.…”

Section: Discussionmentioning

confidence: 99%

<p>Incidence and Predictors of Congestive Heart Failure Among Hemodialysis Patients at Felege Hiote Referral Hospital, Northwest Ethiopia, 2020: Retrospective Cohort Study</p>

Gedfew¹,

Ayenew²,

Mengst³

et al. 2020

RRCC

View full text Add to dashboard Cite

Background: Heart failure is the cumulative and progressive result of conditions that cause structural defects and functional abnormalities in the heart. It is affects at least 26 million people worldwide and is increasing in prevalence especially among hemodialysis patients with severe renal failure. Objective: To assess the incidence and predictors of congestive heart failure among hemodialysis patients at Felege Hiote Referral Hospital, Northwest Ethiopia. Methods: This institutionally based retrospective cohort study was undertaken among 205 hemodialysis patients of Felege Hiote Referral Hospital from January 1, 2016 to February 29, 2020. All eligible hemodialysis patients who fulfilled the inclusion criteria were included in the study. Data were entered using Epi-data Version 4.1 and analyzed using STATA Version 14. The survival time of hemodialysis patients was estimated using the Kaplan-Meier survival curve, and the survival time between different categorical variables was compared using the log rank test. Both bivariable and multivariable Cox-proportional hazard regression models were fitted to identify independent predictors of congestive heart failure among hemodialysis patients. Results: Among a cohort of 205 hemodialysis patients at Felege Hiote Referral Hospital, 12 (5.9%) developed congestive heart failure during the follow-up time. The overall congestive heart failure incidence rate was 2.9 per 100 person-years (PY) with 95% CI. The total time allotted to follow up the study participants was 4968 PY. Using multivariable Cox-regression analysis, we found that male sex, rural residence, no formal education, low body mass index (<18.5), presence of comorbidity, and anemia during dialysis initiation significantly increased the risk of heart failure. Conclusion: In this study, we found a high rate of congestive heart failure among hemodialysis patients. Factors significantly linked with increased risk of heart failure included male sex, rural residence, no education, low body mass index (<18.5), presence of comorbidity, and anemia during dialysis initiation. Early screening and treatment for heart failure are highly recommended at hemodialysis follow-up for patients with the above risk factors.

show abstract

“…Increasing the knowledge about HF costs and their determinants is important in order to ascertain how HF management can be optimized, leading to a signi cant decrease of HF costs [3,7,11,12]. Unfortunately, data about costs of HF in Spain are very scarce or limited to the use of speci c drugs, but not focused on a comprehensive approach [13][14][15][16][17].…”

Section: Introductionmentioning

confidence: 99%

Costs and Healthcare Utilisation of Patients With Heart Failure in Spain

Cervantes

Varela

Palacios³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: To evaluate the cumulative costs and healthcare utilisation in heart failure (HF) patients in Spain. This was also analyzed among the DAPA-HF like population.Methods: Observational, retrospective, population-based study using BIG-PAC database, which included data from specialized and primary care of people aged ≥18 years, from 7 autonomous communities in Spain, who received care for HF between 2015 and 2019. The healthcare and medication costs were summarized on a yearly basis starting from the index date (1st January 2015), and then cumulatively until the last year of follow-up (2019).Results: We identified 17,163 patients with HF (year 2015: mean age 77.3±11.8 years, 53.5% men, 51.7% systolic HF and 43.6% on NYHA functional class II). During the 2015-2019 period, total HF associated costs reached 15,373 Euros per person, being cardiovascular disease hospitalizations the most important determinant (75.8%), particularly HF hospitalizations (51.0%). Total medication cost accounted for 7.0% of the total cost. During this period, there was a progressive decrease of cardiovascular disease hospital costs per year (from 2,834 Euros in 2015 to 2,146 Euros in 2019, P<0.001), as well as cardiovascular and diabetic medication costs. Hospitalization and medication costs were higher in the DAPA-HF like population.Conclusions: During the 2015-2019 period, costs of patients with HF in Spain were substantial, being HF hospitalizations the most important determinant. Medication costs represented only a small proportion of total HF costs. Improving HF management, particularly through the use of those drugs that reduce HF hospitalization may be helpful to reduce HF burden.

show abstract

Burden and challenges of heart failure in patients with chronic kidney disease. A call to action

Cited by 27 publications

References 101 publications

Costs and healthcare utilisation of patients with heart failure in Spain

Costs and healthcare utilisation of patients with heart failure in Spain

<p>Incidence and Predictors of Congestive Heart Failure Among Hemodialysis Patients at Felege Hiote Referral Hospital, Northwest Ethiopia, 2020: Retrospective Cohort Study</p>

Costs and Healthcare Utilisation of Patients With Heart Failure in Spain

Contact Info

Product

Resources

About